© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo
(Reuters) – The U.S. Centers for Disease Control and Prevention (CDC) has closed its investigation on Abbott Laboratories (NYSE:)’ infant formula, with no additional cases of infections, according to a notice on the U.S. Food and Drug Administration website.
The agencies were investigating bacterial infections caused by the infant formula manufactured at Abbott’s Sturgis facility in Michigan.
Be the first to comment